Combination therapy for multidrug-resistant cytomegalovirus disease

Transplant Infectious Disease

Volumn 17, Issue 5, 2015, Pages 751-755

  Stuehler, C ^a   Stussi G ^b   Halter, J ^a   Nowakowska, J ^a   Schibli, A ^a   Battegay, M ^a   Dirks, J ^a   Passweg, J ^a   Heim, D ^a   Rovo, A ^a   Kalberer, C ^a   Bucher, C ^a   Weisser, M ^a   Dumoulin, A ^c   Hirsch, H H ^a,c   Khanna, N ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Adoptive T cell transfer; Allogeneic hematopoietic stem cell transplantation; Cytomegalovirus; Maribavir; Multidrug resistance

Indexed keywords

ARTESUNATE; BENZIMIDAVIR; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; FOSCARNET; LEFLUNOMIDE; METHYLPREDNISOLONE; PROBENECID; RITUXIMAB; VALGANCICLOVIR; ANTIVIRUS AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG WITHDRAWAL; FOLLICULAR LYMPHOMA; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC ANEMIA; HUMAN; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE; ORTHOSTATIC HYPOTENSION; POLYNEUROPATHY; PRIORITY JOURNAL; RETRANSPLANTATION; SPLENECTOMY; VIRUS LOAD; VIRUS REPLICATION; ADOPTIVE TRANSFER; COMBINATION DRUG THERAPY; CYTOMEGALOVIRUS INFECTIONS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY;

ADOPTIVE TRANSFER; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED;

EID: 84943177429     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12435     Document Type: Article

References (16)

1. Peggs KS, Thomson K, Samuel E, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011; 52 (1): 49-57.
2. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113 (23): 5711-5719.
3. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6: 29.
4. Egli A, Binggeli S, Bodaghi S, et al. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant 2007; 22 (Suppl 8): viii72-viii82.
5. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356 (9230): 645-649.
6. Razonable RR. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients. Infect Dis Clin North Am 2013; 27 (2): 317-342.
7. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23 (4): 689-712.
8. He R, Park K, Cai H, et al. Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 2012; 56 (7): 3508-3515.
9. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010; 12 (6): 489-496.
10. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014; 370 (19): 1781-1789.
11. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369 (13): 1227-1236.
12. Sellar RS, Peggs KS. Therapeutic strategies for the prevention and treatment of cytomegalovirus infection. Expert Opin Biol Ther 2012; 12 (9): 1161-1172.
13. Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116 (20): 4360-4367.
14. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201 (7): 1031-1036.
15. Egli A, Bergamin O, Mullhaupt B, Seebach JD, Mueller NJ, Hirsch HH. Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and review of the literature. Transpl Infect Dis 2008; 10 (1): 27-43.
16. + T cell responses against latent viruses: relationship among phenotype, localization, and function. J Virol 2015; 89 (1): 568-580.